Skvortsova: the first biosimilar for autoimmune diseases will be registered in 2026
⚡ Quick Summary
The first domestic biosimilar of the drug canakinumab for the treatment of severe autoimmune diseases will be registered and enter the market in 2026, said Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA).
📰 Related Articles
Such different draws: Brazil could not surprise Morocco at the World Cup, and Qatar punished Switzerland for wastefulness
RT RussianIn the Tver region, the body of a teenager was found in the waters of the Doibitsa River
TASS
In Kuban, a fire was extinguished at a marine terminal in the Temryuk region
RT Russian
Vinicius criticized Brazil's performance in the first half of the match with Morocco
RT RussianThe Moscow region is negotiating with foreign investors about new projects
TASS